User profiles for G. Lanza

Gennaro Lanza

Professor of Finance
Verified email at investoo.eu
Cited by 16133

Nanotechnological applications in medicine

SD Caruthers, SA Wickline, GM Lanza - Current opinion in Biotechnology, 2007 - Elsevier
Nanotechnology-based tools and techniques are rapidly emerging in the fields of medical
imaging and targeted drug delivery. Employing constructs such as dendrimers, liposomes, …

Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management

GA Lanza, F Crea - Circulation, 2010 - Am Heart Assoc
Myocardial ischemia is usually caused by abnormalities of epicardial coronary arteries. In
the past 30 years, however, several studies have shown that abnormalities in coronary …

Mechanisms of coronary artery spasm

GA Lanza, G Careri, F Crea - Circulation, 2011 - Am Heart Assoc
… VSMC contraction, however, is regulated by a complex, not yet fully elucidated, system of
different intracellular pathways that involve various G proteins, enzymes, and regulatory …

A microRNA expression signature of human solid tumors defines cancer gene targets

…, RL Prueitt, N Yanaihara, G Lanza… - Proceedings of the …, 2006 - National Acad Sciences
Small noncoding microRNAs (miRNAs) can contribute to cancer development and
progression and are differentially expressed in normal tissues and cancers. From a large-scale …

[PDF][PDF] Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas

…, X Liu, S Zupo, V Herlea, L Gramantieri, G Lanza… - Cancer cell, 2007 - cell.com
Noncoding RNA (ncRNA) transcripts are thought to be involved in human tumorigenesis. We
report that a large fraction of genomic ultraconserved regions (UCRs) encode a particular …

[BOOK][B] Genetic programming IV: Routine human-competitive machine intelligence

…, MA Keane, MJ Streeter, W Mydlowec, J Yu, G Lanza - 2005 - books.google.com
… Guido Lanza is Vice President of Biology and co-founder of Pharmix Corporation. He received
his BA degree in 1998 from the University of California at Berkeley from the Department of …

CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

…, JA Foekens, SR Hamilton, G Lanza… - Genome …, 2013 - genome.cshlp.org
… transcripts containing G or T have different biological functions. We mutated the SNP site
of the retrovirus CCAT2 construct from G to T and transfected HCT116 cells with CCAT2-G or …

Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With αvβ3-Integrin–Targeted Nanoparticles

…, JS Allen, EK Lacy, JD Robertson, GM Lanza… - Circulation, 2003 - Am Heart Assoc
LanzaLanza … Drs Lanza and Wickline are cofounders, board members, and equity
holders of Kereos, Inc. RW Fuhrhop and JS Allen are consultants to Kereos, Inc. …

Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques

…, GA Sicard, PJ Gaffney, SA Wickline, GM Lanza - Circulation, 2001 - Am Heart Assoc
Background Molecular imaging of thrombus within fissures of vulnerable atherosclerotic
plaques requires sensitive detection of a robust thrombus-specific contrast agent. In this study, …

Microsatellite instability and colorectal cancer prognosis

…, C Oliani, M Ponz de Leon, G Lanza - Clinical Cancer …, 2005 - AACR
Purpose: Many studies have evaluated the role of high levels of microsatellite instability (MSI)
as a prognostic marker and predictor of the response to chemotherapy in colorectal cancer …